Evidence map›Paper›PMID 26416866›Full record

ArticleAntimicrobial agents and chemotherapy2015

Fluoroquinolone Impact on Nasal Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Colonization Durations in Neurologic Long-Term-Care Facilities.

Clotilde Couderc, Anne C M Thiébaut, Christine Lawrence, Coralie Bouchiat, Jean-Louis Herrmann, Jérôme Salomon, Didier Guillemot, Antibiotic Use and Staphylococcus aureus Resistant to Antibiotics Study Group

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Clotilde CoudercInstitut Pasteur, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Paris, France INSERM, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Paris, France Université Versailles St-Quentin, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Montigny le Bretonneux, France clotilde.couderc@gmail.com didier.guillemot@pasteur.fr.
Anne C M ThiébautInstitut Pasteur, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Paris, France INSERM, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Paris, France Université Versailles St-Quentin, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Montigny le Bretonneux, France.
Christine LawrenceAP-HP, Hôpital Raymond-Poincaré, Garches, France.
Coralie BouchiatUniversité Lyon 1, International Center for Infectiology Research (CIRI), Lyon, France INSERM, U1111 International Center for Infectiology Research (CIRI), Lyon, France École Normale Supe´rieure de Lyon, International Center for Infectiology Research (CIRI), Lyon, France CNRS, UMR 5308 International Center for Infectiology Research (CIRI), Lyon, France Hospices Civils de Lyon, Centre National de Référence des Staphylocoques, Bron, France.
Jean-Louis HerrmannAP-HP, Hôpital Raymond-Poincaré, Garches, France Université Versailles St-Quentin, U1173, Saint-Quentin-en-Yvelines, France INSERM, U1173, Montigny le Bretonneux, France.
Jérôme SalomonInstitut Pasteur, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Paris, France INSERM, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Paris, France Université Versailles St-Quentin, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Montigny le Bretonneux, France AP-HP, Hôpital Raymond-Poincaré, Garches, France.
Didier GuillemotInstitut Pasteur, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Paris, France INSERM, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Paris, France Université Versailles St-Quentin, UMR 1181 Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Montigny le Bretonneux, France AP-HP, Hôpital Raymond-Poincaré, Garches, France clotilde.couderc@gmail.com didier.guillemot@pasteur.fr.
Antibiotic Use and Staphylococcus aureus Resistant to Antibiotics Study Group
Hôpital Raymond-Poincaré · FRAssistance Publique – Hôpitaux de Paris · FRCentre National de la Recherche Scientifique · FRInstitut Pasteur · FRUniversité de Versailles Saint-Quentin-en-Yvelines · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus aureus nasal carriage is a risk factor for subsequent infection. Estimates of colonization duration vary widely among studies, and factors influencing the time to loss of colonization, especially the impact of antibiotics, remain unclear. We conducted a prospective study on patients naive for S. aureus colonization in 4 French long-term-care facilities. Data on nasal colonization status and potential factors for loss of colonization were collected weekly. We estimated methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA) colonization durations using the Kaplan-Meier method and investigated factors for loss of colonization using shared-frailty Cox proportional hazards models. A total of 285 S. aureus colonization episodes were identified in 149 patients. The median time to loss of MRSA or MSSA colonization was 3 weeks (95% confidence interval, 2 to 8 weeks) or 2 weeks (95% confidence interval, 2 to 3 weeks), respectively. In multivariable analyses, the methicillin resistance phenotype was not associated with S. aureus colonization duration (P = 0.21); the use of fluoroquinolones (hazard ratio, 3.37; 95% confidence interval, 1.31 to 8.71) and having a wound positive for a nonnasal strain (hazard ratio, 2.17; 95% confidence interval, 1.15 to 4.07) were associated with earlier loss of MSSA colonization, while no factor was associated with loss of MRSA colonization. These results suggest that the methicillin resistance phenotype does not influence the S. aureus colonization duration and that fluoroquinolones are associated with loss of MSSA colonization but not with loss of MRSA colonization.

Indexed as

InstitutionalizationMethicillin ResistanceAdultAnti-Bacterial AgentsColony Count, MicrobialFemaleFluoroquinolonesHumansLong-Term CareMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedNasal CavityNeurodegenerative DiseasesPhenotypeProportional Hazards ModelsAnti-Bacterial AgentsFluoroquinolones

Identifiers

PMID26416866
PMCPMC4649197
OpenAlexW2185552937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.